

CASE REPORT

TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report

Shan Meng¹  | Hailing Liu¹  | Wanggang Zhang¹ | Aili He¹ | Honghong Sun² | Ru Zhang³ | Xiaoli Chen⁴ | Yinxia Chen¹

¹Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

²Medical Imaging Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

³Department of Neurology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

⁴Pathology Department, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Correspondence

Yinxia Chen, Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, West Five Road, NO. 157, Xi'an, Shaanxi Province, China.

Email: chenyx204@163.com

Funding information

Grants from the Second Affiliated Hospital of Xi'an Jiaotong University, Grant/Award Number: 2020YJ(ZYTS)158

Abstract

A man diagnosed as TAFRO syndrome was successfully responded to a novel immunosuppressive regimen containing methylprednisolone and mycophenolate mofetil. Blood cells firstly recovered, followed by the general situation and complete recover 1 month later, highlighting the danger of TAFRO syndrome and the importance of immunosuppressive agents in reversing pathological course.

KEYWORDS

Castleman disease, hematology, immunosuppressive agents, oncology

1 | INTRODUCTION

Castleman disease (CD) is a rare lymphoproliferative disease firstly defined in 1954.¹ It could be divided into two major forms, unicentric CD and multicentric CD (MCD). MCD may cause multiple lymph nodes enlargement and organs dysfunction.² Approximately 50% of patients with MCD who are negative for HIV and HHV8 comprise a subgroup that has been termed as idiopathic MCD (iMCD).³ As a particular subtype of iMCD, TAFRO syndrome was

extremely rare to be reported, which was characterized by thrombocytopenia [T], anasarca [A], fever [F], renal failure [R], and organomegaly [O]. The rarity of TAFRO syndrome has greatly limited the ability to perform systematic studies providing solid evidence of therapeutic strategies. Some of the investigators have tried to synthesize a treatment algorithm for the clinicians.⁴ Here, we report a severely ill patient diagnosed with TAFRO syndrome and successfully responded to combined immunosuppressive regimens, including thalidomide, methylprednisolone

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.

and mycophenolate mofetil. This report will provide effective, safe and inexpensive strategy for patients suffering from this disease who cannot afford those expensive agents.

2 | CASE EXAMINATION AND TREATMENT

A 36-year-old man without special past history was admitted due to fever, chest tightness and shortness of breath on 16 November 2018. After admission, systemic laboratory and imaging examinations were performed, and he was successively treated with antibiotics and supportive treatment. On day 3, since the patient had severe thrombocytopenia, the needle inguinal lymph node biopsy was performed. The results were shown in Figure 1A. On day 8, continuous renal replacement therapy was performed to release swelling. All these strategies did not be effective, and the patient started to show a decrease of limb muscle strength to grade 3 with normal muscle tension. On day 13, PET-CT showed many enlarged lymph nodes, indicating hematological malignancy. At the same time, the platelet (PLT) counts remain under $20 \times 10^9/L$, with a getting worse liver function and general condition. On day 18, a second needle lymph node biopsy was performed. Table 1 shows some important laboratory examination results. Until then, the patient was diagnosed as TAFRO syndrome.

On day 18, prednisone hydroxide (30 mg/d) was added. PLT gradually increased, and pleural effusions were also reduced. On day 22, thalidomide (50 mg/d) was also added. PLT gradually increased to $40 \times 10^9/L$, and the enlarged superficial lymph nodes were also diminished. On day 29, thalidomide was discontinued because of the severe systemic allergic rash. Instead, the experimental chemotherapy COP regimen was given. On day 30, the patient started fever again, accompanied by obvious abdominal distension, then antibiotics were added again to control the potential infection. At this time, his advanced intelligence started retardate. Cranial MRI showed there might be bilateral subfrontal cortex ischemia, and limbs electromyogram showed moderate to the severe lesion of motor branches of peripheral nerves in extremities. Therefore, prednisone hydroxide (30 mg/d) was changed to methylprednisolone (40 mg/d) on day 30 because of its minimal side effect. On day 34, the patient started to show paroxysmal bradycardia during sleep, with the heart rate dropping to 40 beats per minute. Then methylprednisolone dose was increased to 80 mg/d and γ -Globulin (20 g/d), and mycophenolate mofetil (1500 mg/d). On day 36, the patient showed convulsion and seizure like features. Electroencephalogram showed a mild abnormality. After

consulting neurologist, phenobarbital (200 mg/d) and lamotrigine (25 mg/d) were added to control seizure. Other supportive treatments were also persistently performed.

On day 45, the patient's general condition gradually improved. Both imaging and laboratory examinations showed steadily improvement, as shown in Figure 1B. The clinical course and laboratory parameters changes were shown in Figure 1C. On day 64, he was discharged from the hospital.

After a follow-up of 36 months, the patient is still alive with a normal blood routine test result, liver function, and normal muscle strength of his lower limbs, suggesting the durable curative effect of our treatment strategy.

3 | DISCUSSION

In this case, the patient showed intermittent fever, anemia, thrombocytopenia, intensive edema, elevated liver enzymes, renal dysfunction, hypoproteinemia, paralysis of the lower extremity and even arrhythmia and seizure during the course, highlighting the complex manifestations of iMCD. To note, some of the patients diagnosed as iMCD showed more aggressive clinical course and have worse outcomes. They have been proved to have TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly). It has been proved to be a novel subtype of iMCD according to the histopathological similarity of lymph node lesions. And the 5-year survival rate is worse in TAFRO subtype than the others. In our case, the patient fitted TAFRO, which was finally diagnosed with TAFRO syndrome.

Till now, its etiology and pathogenesis remain unclear. It has been speculated that two factors play key roles in it. First is overproduction of IL-6 from germinal center B cells⁵ which can cause lymph node enlargement, plasmacytic infiltration, hepatosplenomegaly, and reactive bone marrow plasmacytosis with polyclonal hypergammaglobulinemia.^{6,7} As reported, we also observed a dramatically decreased IL-6 level after remission (from 18.7 pg/ml to normal). Another factor is autoimmune diseases which will aggravate the condition.⁸ In our case, autoimmune-related examination such as autoantibodies, antineutrophil antibodies and rheumatism series indexes were negative.

For iMCD/TAFRO syndrome treatment, a consensus, evidence-based treatment guidelines were established in 2018.⁹ The monoclonal antibody targeting the interleukin-6 signaling pathway (siltuximab/tocilizumab) with or without corticosteroids is the preferred first-line therapy for these patients with a response rate of single anti-IL-6 mAb 66% (88/144).¹⁰ Rituximab is also a first-line alternative to anti-IL-6 mAb therapy for patients who do not




FIGURE 1 Pathological results and image manifestation during the course. (A) pathological results of lymph nodes. H-E staining and immunohistochemical staining from inguinal lymph node. It showed multiple plasma cells infiltration in the lymph medullary cord. While the complete structure of lymph node sinus and diffused angiogenesis were not typical because of the limitations of fine-needle aspiration biopsy. (B) chest and abdominal CT image changes during the clinical course. (C) the whole clinical course. Abbreviations: COP chemotherapy, cyclophosphamide, vinorelbine and prednisone hydroxide; CRRT, continuous renal replacement therapy; PLT, platelet

have marked cytokine-driven symptomatology.¹¹ In this case, we did not choose tocilizumab or rituximab because of financial reasons.

As a universal and powerful immunosuppressor, corticosteroids are also widely used in iMCD by suppressing the hypercytokinemia in a high dose, which may greatly increase the incidence rate of bacterial infection and sepsis. Furthermore, it has been proved that cessation of therapy or steroid tapering will inevitably cause disease relapse. Therefore, in this case, high dose methylprednisolone was used to control the disease initially, and thalidomide and mycophenolate mofetil were also added in initial disease control, with intermittent treatment gamma globulin transfusion. During the

maintenance setting, the methylprednisolone dose was gradually reduced.

Mycophenolate mofetil is a novel immunosuppressive agent widely used in immune thrombocytopenia and stem cell transplantation.¹² It is considered relatively safe even overdose with a rare incidence rate of seizure.¹³ Though it is not recommended for iMCD treatment, it did show potent efficacy in combination with cyclosporin in a 50-year-old male patient who was finally diagnosed as retroperitoneal hyaline-vascular CD.¹⁴ In our case, the patient also responded well after adding mycophenolate mofetil. Of course, it could not completely be due to mycophenolate mofetil since he might have responded to the earlier agents such as

TABLE 1 Laboratory finds after admission

Test	Value	Normal ranges
White blood cell ($\times 10^9/L$)	12.49	4.0–10.0
Hemoglobin (g/L)	121	131–172
Platelet ($\times 10^9/L$)	42	100–300
Albumin (g/L)	19.9	35–55
Gglobulin (g/L)	30.2	20–40
Serum creatinine ($\mu\text{mol/L}$)	133.97	57–111
ALT (IU/L)	9	9–50
AST (IU/L)	28	15–40
γ -GT (U/L)	87	10–60
IgG (g/L)	13.9	7–16
IgA (g/L)	1.88	0.7–4.0
IgM (g/L)	0.4	0.4–2.3
CRP (mg/L)	232	0–3.5
PT (s)	11.9	10–14
APTT (s)	30.6	23–35
FIB (mg/dl)	562	185–350
D-dimer ($\mu\text{g/L}$)	12,690	<590
FDP (mg/L)	41.76	<5
IL-6 (pg/ml)	18.7	0–14
EBV-DNA (IU/ml)	Negative	$<1 \times 10^3$
CMV-DNA (IU/ml)	Negative	$<1 \times 10^3$
ADAMTS13 activity (%)	76.7	68–131
HIV	Negative	Negative
HHV8 (copy/ml)	Negative	$<1 \times 10^{-3}$
Blood immunofixation electrophoresis	Negative	Negative
Urine immunofixation electrophoresis	Negative	Negative

Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time (s); AST, alanine aminotransferase; CRP, C reactive protein; FDP, fibrinogen degradation product; FIB, fibrinogen; HHV8, human herpes virus 8; HIV, human immunodeficiency virus; IL-6, interleukin-6; PT, prothrombin times (s); γ -GT, γ -glutamyl transpeptidase.

high-dose steroids. Three days after adding mycophenolate mofetil, the patient showed convulsion and seizure like features. The possible reason might be the progression of the disease since he gradually showed a decrease of limb muscle strength and advanced mental retardation before taking mycophenolate mofetil.

For some patients, chemotherapy regimens can also be tried, such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or CVAD (cyclophosphamide, vincristine, adriamycin, etoposide)-like regimens. In this case, we also performed a COP regimen, but the result showed that it did not help. The possible reason may be the deterioration and severity of the condition.

Thalidomide is a potent immunomodulatory agent, which could inhibit the production of several cytokines, including IL-1, IL-6, IL-12, tumor necrosis factor- α , and VEGF, and had been shown treatment activity in iMCD. It is also recommended with or without other agents because of its less toxicity and similar efficacy (69% response).^{15,16} A phase 2 study also proved the effectiveness and safety of an oral thalidomide-cyclophosphamide-prednisone regimen for iMCD patients when tocilizumab or other monoclonal antibodies were unavailable. During our initial treatment, thalidomide was also adopted in combination with corticosteroids, and it did show an increase on PLT count, suggesting it could be a promising choice for these patients.

In conclusion, we reported a case of HIV and HHV-8 negative TAFRO syndrome, which was successfully treated with corticosteroids, thalidomide and mycophenolate mofetil, providing alternative effective, safe and inexpensive strategy for these patients. In the future work, we will use the scheme in more patients in our hospital and patients in other hospitals to verify its effectiveness and safety in a wider range of patients with TAFRO syndrome.

AUTHOR CONTRIBUTIONS

Shan Meng: participated in the whole therapy, summarized clinical data and wrote the articles. Hailing Liu: edited the figures and proofread the manuscript. Wanggang Zhang and Aili He: provided valuable diagnostic information and treatment suggestions. Honghong Sun and Ru Zhang: provided important treatment suggestions. Xiaoli Chen: provided pathological pictures. Yinxia Chen: participated in the whole therapy and guided the article writing.

ACKNOWLEDGEMENTS

We are also indebted to colleagues from the Department of Hematology, the Second Affiliated Hospital of Xi'an Jiaotong University.

FUNDING INFORMATION

This work was supported by Grants from the Second Affiliated Hospital of Xi'an Jiaotong University—Scientific Research Fund (2020YJ[ZYTS]158).

CONFLICT OF INTEREST

None.

DATA AVAILABILITY STATEMENT

The data included in the article are available from the corresponding author upon request.

CONSENT

The informed consent to report individual case and a written informed consent for patient information

and images to be published were both provided by the patient.

ORCID

Shan Meng  <https://orcid.org/0000-0001-7619-2334>

Hailing Liu  <https://orcid.org/0000-0001-6925-1041>

REFERENCES

1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. *Cabot N Engl J Med*. 1954;251:396-400.
2. Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. *Adv Anat Pathol*. 2009;16:236-246.
3. Doi Y, Kitayama H, Yamada M, Miyama Y. Severe complications from an unexpectedly high serum mycophenolic acid concentration in a patient with renal failure secondary to lupus nephritis: a case report case. *Rep Nephrol Dial*. 2019;9:72-78.
4. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. *Nat Rev Drug Discov*. 2018;17:395-412.
5. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. *Clin Cancer Res*. 2013;19:3659-3670.
6. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. *Am J Hematol*. 2003;73:48-53.
7. Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. *Lancet Haematol*. 2016;3:e163-e175.
8. Matsunami M, Ubara Y, Sumida K, et al. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome. *BMC Nephrol*. 2018;19:263.
9. Minemura H, Tanino Y, Ikeda K. Possible Association of Multicentric Castleman's Disease with autoimmune lymphoproliferative syndrome. *Biores Open Access*. 2018;7:47-51.
10. Moritani K, Miyawaki R, Tokuda K, et al. Mesenchymal stem cell therapy overcomes steroid resistance in severe gastrointestinal acute graft-versus-host disease. *Case Rep Transplant*. 2019;2019:7890673-7890675.
11. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. *Am J Hematol*. 2005;78:302-305.
12. Ramasamy K, Gandhi S, Tenant-Flowers M, et al. Rituximab and thalidomide combination therapy for Castleman disease. *Br J Haematol*. 2012;158:421-423.
13. van Rhee F, Greenway A, Stone K. Treatment of idiopathic Castleman disease. *Hematol Oncol Clin North Am*. 2018;32:89-106.
14. van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. *Blood*. 2018;132:2115-2124.
15. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. *Blood*. 1989;74:1360-1367.
16. Yoshizaki K, Murayama S, Ito H, Koga T. The role of Interleukin-6 in Castleman disease. *Hematol Oncol Clin North Am*. 2018;32:23-36.

How to cite this article: Meng S, Liu H, Zhang W, et al. TAFRO syndrome was effectively treated with an inexpensive novel scheme: A case report. *Clin Case Rep*. 2023;11:e06183. doi: [10.1002/ccr3.6183](https://doi.org/10.1002/ccr3.6183)